Condition: Type 1 Diabetes · Sponsor: Augusta University
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
This description comes directly from the study's public registry record.
Ryan A Harris, PhD, CEP · 7067215998 · ryharris@augusta.edu
Jacob Looney, MS · 7067215483 · jlooney@augusta.edu
Always discuss trial participation with your own doctor first.
| Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology | Augusta, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04449198